false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Onconep ...
Novel Radioligand Therapies and Nephrotoxicity
Novel Radioligand Therapies and Nephrotoxicity
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The talk reviewed radioligand therapy (RLT), which combines a tumor-targeting ligand, a stabilizing chelator, and a radioactive payload. Theranostic imaging maps tumor targets before treatment to guide dosing. Approved examples include lutetium-177 therapies for neuroendocrine tumors and PSMA-positive prostate cancer.<br /><br />The kidneys may be exposed when unbound radioligands are filtered and taken up by proximal tubules, causing DNA damage, tubular injury, endothelial damage, and potentially fibrosis or thrombotic microangiopathy. Short-term severe AKI appears uncommon, but emerging studies suggest that kidney function can decline over months, particularly in patients with pre-existing CKD or hypertension. Long-term risks remain uncertain because follow-up data are limited.<br /><br />Protective strategies include individualized dosimetry, hydration, monitoring kidney function and proteinuria, and controlling blood pressure. Amino-acid infusions can reduce proximal-tubule uptake for some therapies, notably lutetium-DOTATATE, but are not effective for PSMA-directed therapy.<br /><br />The speaker emphasized collaboration between nephrologists and oncologists when deciding whether to continue treatment after kidney injury. Treatment decisions should weigh renal risk against expected cancer benefit, while recognizing that evidence on long-term outcomes and comparative safety between RLT types is still developing.
Asset Caption
Raad Bin Zakir Chowdhury, MD, FASN
Meta Tag
Speaker
Raad Bin Zakir Chowdhury
Keywords
radioligand therapy
theranostic imaging
lutetium-177
kidney toxicity
prostate cancer
neuroendocrine tumors
dosimetry
×
Please select your language
1
English